New drug cizutamig enters early trial for thyroid eye disease

NCT ID NCT07597200

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called cizutamig in 38 adults with active, moderate-to-severe thyroid eye disease. The main goal is to see if the drug is safe and tolerable, while also checking how the body processes it and whether it shows any signs of helping the condition. Participants will receive the drug and be monitored closely for side effects and changes in their symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cizutamig (a drug)
What this could lead to
If this works, it could point toward a new treatment option for thyroid eye disease, potentially reducing symptoms like bulging eyes and discomfort.
What could go wrong
This is a very early Phase 1b trial with only 38 people, so it's mainly checking safety. The drug may not work well or could have side effects, and much more research is needed before it could become a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE (TED) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Ninth People's hospital Shanghai Jiaotong University school of medicines

    RECRUITING

    Shanghai, Shanghai Municipality, 200011, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.